Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?

Glioblastoma (GBM) is the most common and lethal form of malignant brain tumor. GBM patients normally undergo surgery plus adjuvant radiotherapy followed by chemotherapy. Numerous studies into the molecular events driving GBM highlight the central role played by the Epidermal Growth Factor Receptor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paula Aldaz, Imanol Arozarena
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	glioblastoma receptor tyrosine kinase tyrosine kinase inhibitors targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/969a531846944fdd90ac8d8676a0e83c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:969a531846944fdd90ac8d8676a0e83c
record_format	dspace
spelling	oai:doaj.org-article:969a531846944fdd90ac8d8676a0e83c2021-11-25T17:04:07ZTyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?10.3390/cancers132257992072-6694https://doaj.org/article/969a531846944fdd90ac8d8676a0e83c2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5799https://doaj.org/toc/2072-6694Glioblastoma (GBM) is the most common and lethal form of malignant brain tumor. GBM patients normally undergo surgery plus adjuvant radiotherapy followed by chemotherapy. Numerous studies into the molecular events driving GBM highlight the central role played by the Epidermal Growth Factor Receptor (EGFR), as well as the Platelet-derived Growth Factor Receptors PDGFRA and PDGFRB in tumor initiation and progression. Despite strong preclinical evidence for the therapeutic potential of tyrosine kinase inhibitors (TKIs) that target EGFR, PDGFRs, and other tyrosine kinases, clinical trials performed during the last 20 years have not led to the desired therapeutic breakthrough for GBM patients. While clinical trials are still ongoing, in the medical community there is the perception of TKIs as a lost opportunity in the fight against GBM. In this article, we review the scientific rationale for the use of TKIs targeting glioma drivers. We critically analyze the potential causes for the failure of TKIs in the treatment of GBM, and we propose alternative approaches to the clinical evaluation of TKIs in GBM patients.Paula AldazImanol ArozarenaMDPI AGarticleglioblastomareceptor tyrosine kinasetyrosine kinase inhibitorstargeted therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5799, p 5799 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	glioblastoma receptor tyrosine kinase tyrosine kinase inhibitors targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	glioblastoma receptor tyrosine kinase tyrosine kinase inhibitors targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Paula Aldaz Imanol Arozarena Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
description	Glioblastoma (GBM) is the most common and lethal form of malignant brain tumor. GBM patients normally undergo surgery plus adjuvant radiotherapy followed by chemotherapy. Numerous studies into the molecular events driving GBM highlight the central role played by the Epidermal Growth Factor Receptor (EGFR), as well as the Platelet-derived Growth Factor Receptors PDGFRA and PDGFRB in tumor initiation and progression. Despite strong preclinical evidence for the therapeutic potential of tyrosine kinase inhibitors (TKIs) that target EGFR, PDGFRs, and other tyrosine kinases, clinical trials performed during the last 20 years have not led to the desired therapeutic breakthrough for GBM patients. While clinical trials are still ongoing, in the medical community there is the perception of TKIs as a lost opportunity in the fight against GBM. In this article, we review the scientific rationale for the use of TKIs targeting glioma drivers. We critically analyze the potential causes for the failure of TKIs in the treatment of GBM, and we propose alternative approaches to the clinical evaluation of TKIs in GBM patients.
format	article
author	Paula Aldaz Imanol Arozarena
author_facet	Paula Aldaz Imanol Arozarena
author_sort	Paula Aldaz
title	Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
title_short	Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
title_full	Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
title_fullStr	Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
title_full_unstemmed	Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
title_sort	tyrosine kinase inhibitors in adult glioblastoma: an (un)closed chapter?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/969a531846944fdd90ac8d8676a0e83c
work_keys_str_mv	AT paulaaldaz tyrosinekinaseinhibitorsinadultglioblastomaanunclosedchapter AT imanolarozarena tyrosinekinaseinhibitorsinadultglioblastomaanunclosedchapter
_version_	1718412790965731328

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?

Ejemplares similares